Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Hayward, California 94545


Purpose:

This study is an open-label study where all subjects will receive active drug, reslizumab. Subjects are able to enter this trial only through completion of study Res-5-0002. The goal of the study is to show longer term safety and efficacy in pediatric subjects who have eosinophilic esophagitis.


Study summary:

Subjects will enter this open-label extension study after completing the placebo-controlled, double-blind study Res-5-0002. The end of study visit for Res-5-0002 will serve as the screening visit for this trial. All subjects will receive reslizumab and be followed by their principal investigators in an unblinded fashion. Visits and administration of reslizumab will be monthly.


Criteria:

Inclusion Criteria: - Informed consent - Received at least two doses of study drug in Study 5-0002 - Did not withdraw from Study 5-0002 due to drug related AE - Completed End of Treatment Visit for Study 5-0002 Exclusion Criteria: - Pregnant or nursing females - Concurrent Immunodeficiency - Current use of immunosuppressive drugs - Did not tolerate study drug in Study 5-0002


NCT ID:

NCT00635089


Primary Contact:

Study Director
Sponsor's Medical Expert, MD
Cephalon


Backup Contact:

N/A


Location Contact:

Hayward, California 94545
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.